Clinical trials: Major Depressive Disorder, completed
Type1diabetes, Depressive Symptoms
Type 1 Diabetes and Depression: Role of Brain Glutamate
The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with…
- Conditions
- Type1diabetes, Depressive Symptoms, Major Depressive Disorder
- Trial name
- NCT05355285
- Testing
- Glucose Clamp
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Depressive Disorder, Major
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
- Trial name
- NCT00105989
- Testing
- Duloxetine
- Where
- 34 sites in United States, France and 4 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Obesity, Major Depressive Disorder
Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)
To determine whether individuals who suffer from depression and obesity are able to lose weight and show improvements in mood and cardiovascular disease risk factors following 20 weeks of a combined treatment of…
- Conditions
- Obesity, Major Depressive Disorder, Dysthymic Disorder, Cardiovascular Disease
- Trial name
- TODI (NCT01692574)
- Testing
- Behavior Modification for Weight Loss, Alternative Approach to Weight Loss, Cognitive-Behavior Therapy for Depression
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Pennsylvania
Depression
Rhodiola Rosea Therapy of Major Depressive Disorder
Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs.
- Trial name
- NCT01098318
- Testing
- Herbal extract, Sertraline, Lactose monohydrate
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Accelerated rTMS for Treatment-Resistant Major Depression
High frequency repetitive transcranial magnetic stimulation (HF-rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks.
- Trial name
- NCT02125799
- Testing
- Accelerated HF-rTMS (Magstim Rapid 2 stimulator)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Douglas Mental Health University Institute
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder (MDD)
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.
- Trial name
- NCT00411242
- Testing
- agomelatine
- Where
- 51 sites in United States
- Volunteers
- 503 people
- Sponsor
- Novartis
Depression, Major Depressive Disorder
Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
The purpose of the study is to learn more about computer-assisted cognitive behavioral therapy or "CCBT" and to examine connections in the brains of patients with depression.
- Conditions
- Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar
- Trial name
- NCT03096886
- Testing
- Computer-Augmented Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depressive Disorder, Major
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.
- Trial name
- NCT02116361
- Testing
- onabotulinumtoxinA, Normal Saline
- Where
- 35 sites in United States
- Volunteers
- 258 people
- Sponsor
- Allergan
Depression, Anger
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism
Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery.
- Conditions
- Depression, Anger, Anxiety, Alcoholism
- Trial name
- NCT00197951
- Testing
- Treatment of psychiatric symptoms associated to alcoholism
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Major Depression
Thyroid Medication and Antidepressants for Treating Major Depression
This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder…
- Trial name
- NCT00208702
- Testing
- Triiodothyronine, Sertraline
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Emory University
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression, Anxiety Disorder
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment
The aim of the study is to determine the influence of supplementation of probiotic Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with SSRI (Selective Serotonin Reuptake Inhibitor) in…
- Trial name
- NCT02469545
- Testing
- Lactobacillus Plantarum 299v, Crystalline cellulose powder, Escitalopram
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Major Depressive Disorder
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
This is a study to assess the distribution, metabolism and excretion of [14C]AZD6765 after a single-dose intravenous administration.
- Trial name
- AZD6765 (NCT01217645)
- Testing
- 150 mg [14C] AZD6765
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
Oral Multiple-dose Study in Patients With Major Depressive Disorder
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
- Trial name
- NCT01924520
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder, Depression
Testing a Transdiagnostic TMS Treatment Target
The goal of this clinical trial is to test a new brain stimulation treatment target for individuals with depression plus at least one additional psychiatric disorder.
- Conditions
- Major Depressive Disorder, Depression, Psychiatric Disorder, Mood Disorders
- Trial name
- T5 (NCT06282146)
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective…
- Trial name
- NCT01941043
- Testing
- CERC-301
- Where
- 24 sites in United States
- Volunteers
- 1,357 people
- Sponsor
- Avalo Therapeutics, Inc.
Late-life Depression, Major Depressive Disorder
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
This study addresses the unmet medical problem of insufficient treatment of late life depression (LLD). Compared with depression in early adulthood, treatment options of LLD are limited.
- Conditions
- Late-life Depression, Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent
- Trial name
- CBTlate (NCT03735576)
- Testing
- Psychotherapy, Questionnaires, Magnetic Resonance Imaging
- Where
- 7 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University of Cologne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.